Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/19223
Title: Pharmacogenetics of Doxorubicin in Asian Breast Cancer Patients
Authors: SUMAN LAL CHIRAMMAL SUGUNAN
Keywords: Pharmacogenetics, Doxorubicin, Asian Breast Cancer Patients
Issue Date: 3-Sep-2008
Source: SUMAN LAL CHIRAMMAL SUGUNAN (2008-09-03). Pharmacogenetics of Doxorubicin in Asian Breast Cancer Patients. ScholarBank@NUS Repository.
Abstract: The thesis aimed to comprehensively evaluate the pharmacogenetics of the regulatory nuclear receptor Pregnane-X Receptor (PXR), influx (SLC22A16) and efflux drug transporters (ABCB1, ABCG2, ABCC5, ABCB5 and RLIP76) and drug metabolizing enzymes (CBR1, CBR3) across the biochemical pathway of doxorubicin in Asian breast cancer patients receiving doxorubicin based adjuvant chemotherapy. The study showed that functional polymorphisms in the PXR (*1B haplotype), ABCB1 (linked 1236CC-2677GG-3435CC genotypes), ABCC5 (c.-1679T), SLC22A16 (c.146A>G) and CBR1 (D2 diplotype) genes may significantly contribute to the heterogeneity in doxorubicin disposition among Asian breast cancer patients. It is conceivable that the observed polygenic influence on doxorubicin pharmacogenetics may also influence efficacy of doxorubicin in patients receiving adjuvant chemotherapy. Development and independent validation of multi-compartmental pharmacokinetic-pharmacodynamic models that succinctly incorporate both genetic and non-genetic factors will be invaluable in definitively establishing the clinical utility of findings in the present study on doxorubicin pharmacogenetics.
URI: http://scholarbank.nus.edu.sg/handle/10635/19223
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
PhD Thesis -Suman Lal Chirammal Sugunan FOM, NUS - 2008.pdf1.86 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

323
checked on Dec 11, 2017

Download(s)

459
checked on Dec 11, 2017

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.